Overall Winner: Nabla·73/ 100
N
NablaWinner
VS

Nabla vs Qure.ai

In-depth comparison — valuation, funding, investors, founders & more

Winner
N
Nabla

🇫🇷 France · Alexandre Lebrun

Series BAI HealthcareEst. 2018

Valuation

$180M

Total Funding

$30M

73
Awaira Score73/100

80 employees

Full Nabla Profile →
Q
Qure.ai

🇮🇳 India · Prashant Warier

Series DAI HealthcareEst. 2016

Valuation

$270M

Total Funding

$157M

70
Awaira Score70/100

250 employees

Full Qure.ai Profile →
🔬

Analyst Summary

Generated from real data · No AI hallucinations

Both Nabla and Qure.ai compete directly in the AI Healthcare space, making this a head-to-head matchup within the same market segment. Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows. Qure.

Qure.ai ($270M) is valued slightly higher than Nabla ($180M). On the funding side, Qure.ai has raised $157M in total — $127M more than Nabla's $30M.

Qure.ai has 2 years more market experience, having been founded in 2016 compared to Nabla's 2018 founding. In terms of growth stage, Nabla is at Series B while Qure.ai is at Series D — a meaningful difference for investors evaluating risk and upside.

Nabla operates out of 🇫🇷 France while Qure.ai is based in 🇮🇳 India, giving each a distinct home-market advantage. On Awaira's 0–100 composite score, both companies are closely matched — Nabla scores 73 and Qure.ai scores 70.

Metrics Comparison

MetricNablaQure.ai
💰Valuation
$180M
$270MWINS
📈Total Funding
$30M
$157MWINS
📅Founded
2018WINS
2016
🚀Stage
Series B
Series D
👥Employees
80
250
🌍Country
France
India
🏷️Category
AI Healthcare
AI Healthcare
Awaira Score
73WINS
70

Key Differences

💰

Valuation gap: Qure.ai is valued 1.5x higher ($270M vs $180M)

📈

Funding gap: Qure.ai has raised $127M more ($157M vs $30M)

📅

Market experience: Qure.ai has 2 years more (founded 2016 vs 2018)

🚀

Growth stage: Nabla is at Series B vs Qure.ai at Series D

👥

Team size: Nabla has 80 employees vs Qure.ai's 250

🌍

Market base: 🇫🇷 Nabla (France) vs 🇮🇳 Qure.ai (India)

⚔️

Direct competitors: Both operate in the AI Healthcare market segment

Awaira Score: Nabla scores 73/100 vs Qure.ai's 70/100

Which Should You Choose?

Use these signals to make the right call

N

Choose Nabla if…

Top Pick
  • Higher Awaira Score — 73/100 vs 70/100
  • France-based for regional compliance or proximity
  • Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows
Q

Choose Qure.ai if…

  • More established by valuation ($270M)
  • Stronger investor backing — raised $157M
  • More market experience — founded in 2016
  • India-based for regional compliance or proximity
  • Qure

Funding History

Nabla raised $30M across 1 round. Qure.ai raised $157M across 5 rounds.

Nabla

Seed

Jan 2018

Qure.ai

Series D

Jan 2021

$81M

Series C

Jan 2020

$50M

Series B

Jan 2018

$20M

Series A

Jan 2017

Lead: Accel Partners

$6M

Seed

Jan 2016

Investor Comparison

No shared investors detected between these two companies.

Unique to Qure.ai

Accel PartnersBessemer Venture PartnersGoogle

Users Also Compare

FAQ — Nabla vs Qure.ai

Is Nabla bigger than Qure.ai?
By valuation, Qure.ai is the larger company at $270M versus $180M — a 1.5x difference. Size can also be measured by team: Nabla employs 80 people while Qure.ai has 250 employees.
Which company raised more funding — Nabla or Qure.ai?
Qure.ai has raised more in total funding at $157M, compared to Nabla's $30M — a gap of $127M. Combined, the two companies have completed 6 known funding rounds.
Which company has a higher Awaira Score?
Nabla holds the higher Awaira Score at 73/100, compared to Qure.ai's 70/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 3-point gap that reflects meaningful differences in scale or traction.
Who founded Nabla vs Qure.ai?
Nabla was founded by Alexandre Lebrun in 2018. Qure.ai was founded by Prashant Warier in 2016. Visit each company's profile on Awaira for a full founder biography.
What does Nabla do vs Qure.ai?
Nabla: Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows. The company has raised $30M in total funding and operates at Series B stage with a valuation of $200M. Nabla's core offering focuses on AI-powered clinical documentation tools designed to reduce administrative burden on healthcare providers. The platform leverages natural language processing and machine learning to automate medical note-taking, allowing physicians to spend more time with patients rather than on paperwork. The company targets hospitals, clinics, and healthcare systems across Europe, with particular strength in the French market. Nabla's technology integrates with existing electronic health record systems and clinical workflows. The company competes in the growing digital health and healthcare AI sector alongside players focused on clinical automation and documentation efficiency. Nabla's approach emphasizes practical integration into existing healthcare infrastructure rather than building standalone applications. The company has demonstrated traction in European healthcare markets where administrative burden on clinicians remains significant. Its Series B funding stage indicates successful product-market fit validation and positions Nabla for expanded market reach and product development in the healthcare AI space. Nabla addresses the specific pain point of clinical documentation burden through AI automation, allowing European healthcare providers to improve operational efficiency. Qure.ai: Qure.ai is an Indian artificial intelligence company founded in 2016 that develops machine learning solutions for diagnostic imaging in healthcare. The company specializes in computer-aided detection and diagnosis systems that analyze medical imaging data including chest X-rays, CT scans, and mammograms to identify abnormalities and assist radiologists in clinical decision-making. Its platform uses deep learning algorithms trained on large datasets to detect conditions such as tuberculosis, COVID-19, lung cancer, and other pathologies. Qure.ai's products are deployed across hospitals and diagnostic centers in India and internationally, serving both institutional healthcare providers and diagnostic chains. The company has secured $157 million in total funding and operates at Series D stage with a valuation of $300 million as of recent rounds. Its technology addresses the shortage of radiologists in developing markets while improving diagnostic accuracy and turnaround times. Qure.ai competes in the medical AI space alongside companies like IBM Watson Health, Zebra Medical Vision, and various regional diagnostic AI providers. The company has demonstrated strong traction in the Indian healthcare market and has expanded its reach to international markets. Its growth trajectory reflects increasing adoption of AI-assisted diagnostic solutions globally and the rising demand for scalable healthcare technologies in resource-constrained settings. Qure.ai focuses specifically on diagnostic imaging AI for markets with radiologist shortages, positioning it distinctly within underserved geographies.
Which company was founded first?
Qure.ai was founded first in 2016, giving it 2 years of additional market experience. Nabla was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.
Which company has more employees?
Nabla has approximately 80 employees, while Qure.ai has approximately 250. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.
Are Nabla and Qure.ai competitors?
Yes, Nabla and Qure.ai are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.